Clinical trials: Cystic Fibrosis
Idiopathic Granulomatous Mastitis, Granulomatous Mastitis
GRAnulomatous MAstitis REGistry Study
Idiopathic granulomatous mastitis (IGM) is a rare benign inflammatory breast condition with unknown cause, affecting approximately 2.4 per 100,000 women aged 20-40 years.
- Trial name
- GRAMAREG (NCT07422870)
- Where
- 2 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- European Breast Cancer Research Association of Surgical Trialists
Cystic Fibrosis
Pulmonary Vascular Disease in CF
In this project, the investigators seek to understand the role of endothelial cells in Cystic Fibrosis (CF) lung disease. This objective will be achieved by conducting a cross sectional clinical study to define the morphology of…
- Trial name
- CF (NCT04549077)
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cystic Fibrosis
Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients
In this observational study, the investigators evaluate the sensitivity of T1-MRI to identify lung perfusion changes in pediatric patients with CF (age = 6-11) before and after initiating FDA-approved Trikafta therapy.
- Trial name
- NCT04994301
- Testing
- Lung T1 MRI
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- University Hospitals Cleveland Medical Center
Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
This study will be a prospective, observational study of patients who undergo endoscopic sinus surgery for cystic fibrosis-related chronic rhinosinusitis (CRS).
- Trial name
- NCT04469439
- Where
- 9 sites in United States
- Volunteers
- 170 people
- Sponsor
- University of California, Los Angeles
Cystic Fibrosis in Children, Cystic Fibrosis
Sinus Disease in Young Children With Cystic Fibrosis
This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young…
- Conditions
- Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder
- Trial name
- NCT06191640
- Testing
- Ivacaftor or elexacaftor/tezacaftor/ivacaftor
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of California, Los Angeles
Cystic Fibrosis (CF)
Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.
The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary modulators SION-2222 and SION-109 in healthy…
- Trial name
- NCT07035990
- Testing
- SION-451, SION-2222, SION-109
- Where
- 2 sites in Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sionna Therapeutics Inc.
Cystic Fibrosis (CF)
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.
- Trial name
- PreciSION CF (NCT07108153)
- Testing
- SION-719
- Where
- 13 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Sionna Therapeutics Inc.
Cystic Fibrosis, Cystic Fibrosis Liver Disease
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) triple combination therapy in people with cystic fibrosis initially…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children, Adherence, Medication
- Trial name
- RECOVER (NCT04602468)
- Testing
- Elexacaftor/Tezacaftor/Ivacaftor
- Where
- 7 sites in Ireland, United Kingdom
- Volunteers
- 206 people
- Sponsor
- Royal College of Surgeons, Ireland
Non-cystic Fibrosis Bronchiectasis
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic respiratory disease characterized by a clinical syndrome of chronic productive cough and recurrent respiratory infections in the presence of abnormal and permanent dilation…
- Trial name
- NCT07245407
- Testing
- Participant Follow-up
- Where
- 38 sites in China
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Bronchiectasis, Non-Cystic Fibrosis, High Intensity Interval Exercise
High-Intensity Interval Exercise in Bronchiectasis Patients
The aim of our study is to investigate the effect of high-intensity interval exercise (HIIE) on the symptoms of bronchiectasis in patients with the disease. The main questions it aims to answer are: 1.
- Trial name
- NCT07805174
- Testing
- high-intensity interval exercise, Airway clearance tecniques
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Cystic Fibrosis
Comparison of Physical Activity, Exercise Capacity, Quality of Life, Cognitive Function and Coronavirus Phobia Levels of Adult Cystic Fibrosis Patients With Healthy Individuals With Telerehabilitation
The purpose of this study was to evaluate physical activity, exercise capacity, quality of life, cognitive status level and coronavirus phobia level of adult cystic fibrosis patients and compare with the findings of healthy…
- Trial name
- NCT04673331
- Testing
- exercise capacity
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Pancreatic Insufficiency, Cystic Fibrosis-related Diabetes
Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis
This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal…
- Trial name
- NCT06995651
- Testing
- Dorzagliatin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Michael R. Rickels, MD, MS
Cystic Fibrosis
Sildenafil Exercise: Role of PDE5 Inhibition
Exercise intolerance is an understudied phenomenon in people with CF. The investigators hypothesized that vascular dysfunction plays a significant role, and can be partially reversed by administration of the phosphodiesterase…
- Trial name
- NCT04039087
- Testing
- Sildenafil 40mg oral capsule
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Jewish Health
Covid19, Cystic Fibrosis
COVID-19 Antibody Responses In Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due…
- Trial name
- CAR-CF (NCT04863573)
- Where
- 11 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Queen's University, Belfast
Cystic Fibrosis
Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis
In this exploratory study, the hormonal responses to a mixed meal will be examined in people with cystic fibrosis. The aim of this study is to find correlates with impaired glucose tolerance that is associated with this…
- Trial name
- NCT06163482
- Testing
- Mixed meal
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Cystic Fibrosis, Constipation
Assessing Tenapanor as a Treatment of CF-related Constipation.
Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients.
- Trial name
- NCT06810167
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Cystic Fibrosis (CF)
MRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO)
Cystic fibrosis (CF) is an inherited condition that affects several organs, including the gut. People with CF often experience uncomfortable digestive symptoms such as bloating, gas, abdominal pain, and constipation.
- Trial name
- FEMPTO (NCT07780344)
- Testing
- Linaclotide 290 micrograms
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Nottingham
Non-cystic Fibrosis Bronchiectasis, Chronic Mucus Hypersecretion
Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH
This pilot RCT will assess benefits of Simeox technology on lung function, respiratory symptoms, health-related quality of life, subjective efficiency, device adherence at home, Patient satisfaction, tolerance, safety, and…
- Trial name
- NCT06237348
- Testing
- Simeox, Control
- Where
- 2 sites in Poland
- Volunteers
- 50 people
- Sponsor
- Physio-Assist
Cystic Fibrosis
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
- Trial name
- NCT06237335
- Testing
- RCT2100, Ivacaftor
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- ReCode Therapeutics
Cystic Fibrosis, Infections
Remote Sputum Collection in Cystic Fibrosis
Elexacaftor/Tezacaftor/Ivacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production.
- Trial name
- RESCUe (NCT06950892)
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania